Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03147885 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 2026 to Dec 2027
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 69 to confirmed 43
    • Site details revised
    v11
  2. Primary completion date: Dec 2025 to Dec 2026
    • Study completion date: Dec 2026 to Dec 2027
    v10
  3. Enrollment target: 44 to 69
    • Primary completion date: Dec 2024 to Dec 2025
    • Study sites: 2 to 1
    • Study completion date: Dec 2024 to Dec 2026
    v9
  4. Primary completion date: Dec 2022 to Dec 2024
    • Study completion date: Dec 2023 to Dec 2024
    v8
  5. Primary completion date: Dec 2021 to Dec 2022
    • Study sites: 3 to 2
    • Study completion date: Dec 2021 to Dec 2023
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Site details revised at 3 of 3 sites
    • Eligibility criteria expanded, about 1 word
    v6
  2. Primary and study completion dates: Jun 2020 to Dec 2021
    • Study sites: 1 to 3
    v5
  3. Primary completion date: Jun 29, 2018 to Jun 2020
    • Study completion date: Dec 28, 2018 to Jun 2020
    v4
  4. Start date changed from estimate of May 2017 to Jun 20, 2017
    • Site contact updated
    v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Barbara Ann Karmanos Cancer Institute
24 trials monitored
See 3 trials at risk
Non-Hodgkin Lymphoma
2,013 trials monitored
See 115 trials at risk
DLBCL
703 trials monitored
See 44 trials at risk
Follicular Lymphoma
347 trials monitored
See 28 trials at risk
and 1 more disease
This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maximum tolerated dose of Selinexor in combination with RCHOP and also study the efficacy of this combination for therapy of B cell Non-Hodgkin's lymphoma. Giving Selinexor plus chemotherapy may work better in treating patients with B cell non-Hodgkin lymphoma.
Trial Details
NCT Number NCT03147885
Lead Sponsor Barbara Ann Karmanos Cancer Institute
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia +7 more
Related terms Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia
Enrollment 43 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov